By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
vantagefeed.comvantagefeed.comvantagefeed.com
Notification Show More
Font ResizerAa
  • Home
  • Politics
  • Business
  • Tech
  • Health
  • Environment
  • Culture
  • Caribbean News
  • Sports
  • Entertainment
  • Science
Reading: Hims & Hers reports 52% YoY increase in Q2 2024 revenue, with digital health revenue also growing
Share
Font ResizerAa
vantagefeed.comvantagefeed.com
  • Home
  • Politics
  • Business
  • Tech
  • Health
  • Environment
  • Culture
  • Caribbean News
  • Sports
  • Entertainment
  • Science
Search
  • Home
  • Politics
  • Business
  • Tech
  • Health
  • Environment
  • Culture
  • Caribbean News
  • Sports
  • Entertainment
  • Science
Have an existing account? Sign In
Follow US
vantagefeed.com > Blog > Health > Hims & Hers reports 52% YoY increase in Q2 2024 revenue, with digital health revenue also growing
Hims & Hers reports 52% YoY increase in Q2 2024 revenue, with digital health revenue also growing
Health

Hims & Hers reports 52% YoY increase in Q2 2024 revenue, with digital health revenue also growing

Vantage Feed
Last updated: August 7, 2024 2:45 am
Vantage Feed Published August 7, 2024
Share
SHARE

Direct-to-consumer virtual care company Hims & Hers Health reported revenues growing 52% year over year, from $207.9 million in Q2’23 to $315.6 million in Q2’24.

The San Francisco-based company reported second-quarter net income of $13.3 million, compared with a net loss of $7.2 million in the same period a year ago.

Adjusted EBITDA was $39.3 million in the second quarter of 2024, up from $10.6 million in the second quarter of 2023, and free cash flow was $47.6 million compared to $10.0 million at the end of last year’s second quarter.

The company raised its full-year 2024 revenue outlook to $1.4 billion from $1.37 billion and adjusted EBITDA to $155 million from $140 million.

“Our second quarter results represent an acceleration of an already incredible trajectory, as we approached 1.9 million subscribers on our platform during the quarter, up 43% year over year,” Andrew Dudum, co-founder and CEO of Hims & Hers, said in a statement.

“As our platform’s capabilities expand, we become more and more confident that we can help every single person in every home across the country feel great.”


Telemedicine Company Talkspace reported second-quarter financial results, revealing that revenue increased 29% year over year to $46.1 million, driven by a 62% increase in payer revenue and a 20% increase in revenue from its Direct-to-Enterprise division.

The company reported that consumer revenue as of Q2 2024 was down 28% year over year.

Operating expenses increased 1% year over year to $24.4 million due to higher administrative and general expenses.

Gross profit increased 18% year over year to $21 million, while gross margin decreased to 45.5% in the second quarter of 2024 from 50% in the same period last year.

Net loss improved to $500,000 from $4.7 million a year earlier, which the company said was mainly due to increased revenue.

Adjusted EBITDA will be $1.2 million in 2Q24, improving from a loss of $4 million in 2Q23.

The company’s financial outlook for the current fiscal year remained unchanged.

“Our strong second quarter performance reflects continued execution with 29% revenue growth and our second consecutive quarter of positive Adjusted EBITDA. We expanded our coverage to more than 145 million people, launched Medicare in 12 states and made significant progress in optimizing our marketing efforts,” Talkspace CEO Dr. John Cohen said in a statement.

“This positive momentum stems from our ongoing efforts to improve both the provider experience and the patient journey while focusing on product quality, a key differentiator for Talkspace. I am encouraged by our accomplishments, which highlight our commitment to making quality mental health care more accessible.”


Clover HealthThe Tennessee-based Medicare Advantage insurtech company reported second-quarter 2024 earnings, with revenue up 11% to $356.3 million from $320.1 million in the same period last year.

The company reported GAAP net income of $7.2 million in the second quarter of this year, but a loss of $28.9 million in the second quarter of 2023.

Adjusted EBITDA increased to $36.2 million from $9.9 million in the second quarter of 2023.

Clover raised its full-year revenue guidance to a range of $1.35 billion to $1.375 billion and its adjusted EBITDA guidance to a range of $50 million to $65 million.

“We achieved our first quarterly GAAP net income as a public company and our adjusted EBITDA increased sequentially compared to the prior quarter,” Clover Health CFO Peter Kuipers said in a statement.

“This strong performance further strengthens our already strong balance sheet position and allows us to improve our full-year 2024 guidance. With our operating performance and our recent recalculation of our star rating for the 2025 payment year from 3 stars to 3.5 stars, we believe we are well positioned to achieve an increase in our 2024 adjusted EBITDA guidance and improve our underlying cohort economics for 2025 to enhance our long-term earnings potential.”

You Might Also Like

Q&A: Building nurses’ trust in AI through education

Humana is working with Dream Health to increase access to its members

Portal Access secures $7 million for chemotherapy ports

CoreLine Soft Scores Imaging AI Supply Contracts include the UK’s NHS, Boehringer Ingelheim, and other briefs.

How to build a nighttime routine for the whole family

TAGGED:DigitalgrowingHealthHimsincreasereportsrevenueYoY
Share This Article
Facebook Twitter Email Print
Leave a comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Follow US

Find US on Social Medias
FacebookLike
TwitterFollow
YoutubeSubscribe
TelegramFollow

Weekly Newsletter

Subscribe to our newsletter to get our newest articles instantly!

Subscribe my Newsletter for new posts, tips & new Articles. Let's stay updated!

Popular News
‘Waging a war on science’: Researchers worry about their jobs under Trump 2.0
Environment

‘Waging a war on science’: Researchers worry about their jobs under Trump 2.0

Vantage Feed Vantage Feed December 15, 2024
‘It was a box office flop’: Frank Darabont and Morgan Freeman on ‘The Shawshank Redemption’s path from failure to classic
Ex machina of venom? Exploring the potential of cell-free protein production for venom biodiscovery
From a healthy heart to improving mood, here’s how water can boost your body
First bird flu infection detected without contact with animals
- Advertisement -
Ad imageAd image
Global Coronavirus Cases

Confirmed

0

Death

0

More Information:Covid-19 Statistics

Importent Links

  • About Us
  • Privacy Policy
  • Terms of Use
  • Contact
  • Disclaimer

About US

We are a dedicated team of journalists, writers, and editors who are passionate about delivering high-quality content that informs, educates, and inspires our readers.

Quick Links

  • Home
  • My Bookmarks
  • About Us
  • Contact

Categories & Tags

  • Business
  • Science
  • Politics
  • Technology
  • Entertainment
  • Sports
  • Environment
  • Culture
  • Caribbean News
  • Health

Subscribe US

Subscribe my Newsletter for new posts, tips & new Articles. Let's stay updated!

© 2024 Vantage Feed. All Rights Reserved.
Welcome Back!

Sign in to your account

Lost your password?